Cargando…

Feasibility outcomes of a randomised, multicentre, pilot trial comparing standard 6-monthly dosing of adjuvant zoledronate with a single one-time dose in patients with early stage breast cancer

BACKGROUND: Adjuvant zoledronate is widely used in patients with early stage breast cancer (EBC), but its optimal duration and dosing interval is still unknown. While a single-dose of zoledronate can improve bone density for many years, a proper evaluation of its effects on breast cancer-related out...

Descripción completa

Detalles Bibliográficos
Autores principales:	Awan, Arif, Ng, Terry, Conter, Henry, Raskin, William, Stober, Carol, Simos, Demetrios, Pond, Greg, Dhesy-Thind, Sukhbinder, Mates, Mihaela, Kumar, Vikaash, Fergusson, Dean, Hutton, Brian, Saunders, Deanna, Vandermeer, Lisa, Clemons, Mark
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7782555/ https://www.ncbi.nlm.nih.gov/pubmed/33425673 http://dx.doi.org/10.1016/j.jbo.2020.100343

Ejemplares similares

A Randomized Trial Comparing 3- versus 4-Monthly Cardiac Monitoring in Patients Receiving Trastuzumab-Based Chemotherapy for Early Breast Cancer
por: Dent, Susan, et al.
Publicado: (2021)

Adjuvant bisphosphonate use in patients with early stage breast cancer: a physician survey
por: McGee, Sharon, et al.
Publicado: (2021)

Adjuvant bisphosphonate use in patients with early stage breast cancer: Patient perspectives on treatment acceptability and potential de-escalation
por: McGee, Sharon, et al.
Publicado: (2021)

Cost-Effectiveness Analysis of 12-Versus 4-Weekly Administration of Bone-Targeted Agents in Patients with Bone Metastases from Breast and Castration-Resistant Prostate Cancer
por: Tu, Megan M., et al.
Publicado: (2021)

Randomised feasibility trial to compare three standard of care chemotherapy regimens for early stage triple-negative breast cancer (REaCT-TNBC trial)
por: Hilton, John, et al.
Publicado: (2018)

Effects on bone resorption markers of continuing pamidronate or switching to zoledronic acid in patients with high risk bone metastases from breast cancer
por: Hilton, J.F., et al.
Publicado: (2017)

Real-world practice patterns and attitudes towards de-escalation of bone-modifying agents in patients with bone metastases from breast and prostate cancer: A physician survey
por: AlZahrani, Mashari, et al.
Publicado: (2020)

A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer
por: Clemons, Mark, et al.
Publicado: (2021)

Perceptions around bone-modifying agent use in patients with bone metastases from breast and castration resistant prostate cancer: a patient survey
por: Alzahrani, Mashari, et al.
Publicado: (2021)

Oral magnesium supplements for cancer treatment‐induced hypomagnesemia: Results from a pilot randomized trial
por: Awan, Arif, et al.
Publicado: (2021)

Doxycycline-Induced Changes in Circulating MMP or TIMP2 Levels Are Not Associated with Skeletal-Related Event-Free or Overall Survival in Patients with Bone Metastases from Breast Cancer
por: Zhao, Huijun, et al.
Publicado: (2023)

The Rethinking Clinical Trials (REaCT) Program. A Canadian-Led Pragmatic Trials Program: Strategies for Integrating Knowledge Users into Trial Design
por: Saunders, Deanna, et al.
Publicado: (2021)

Two-year results of a randomised trial comparing 4- versus 12-weekly bone-targeted agent use in patients with bone metastases from breast or castration-resistant prostate cancer
por: Clemons, Mark, et al.
Publicado: (2021)

A Randomized Controlled Trial Comparing Alloderm-RTU with DermACELL in Immediate Subpectoral Implant-Based Breast Reconstruction
por: Arnaout, Angel, et al.
Publicado: (2020)

A multi-centre study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of docetaxel-cyclophosphamide induced febrile neutropenia
por: Clemons, Mark, et al.
Publicado: (2021)

A systematic review of dosing frequency with bone-targeted agents for patients with bone metastases from breast cancer
por: Hutton, Brian, et al.
Publicado: (2013)

Targeted metabolomics in colorectal cancer: a strategic approach using standardized laboratory tests of the blood and urine
por: Jerzak, Katarzyna J, et al.
Publicado: (2017)

Detection of Macrotroponin in Patients Receiving Treatment for Breast Cancer
por: Kavsak, Peter A., et al.
Publicado: (2023)

A randomized trial of individualized versus standard of care antiemetic therapy for breast cancer patients at high risk for chemotherapy-induced nausea and vomiting
por: Clemons, M., et al.
Publicado: (2020)

Bone-Targeted Agents for the Management of Breast Cancer Patients with Bone Metastases
por: Simos, Demetrios, et al.
Publicado: (2013)

Statin therapy in the treatment of active cancer: A systematic review and meta-analysis of randomized controlled trials
por: Farooqi, Mohammed A. M., et al.
Publicado: (2018)

Breaking silence: a survey of barriers to goals of care discussions from the perspective of oncology practitioners
por: Piggott, Katrina Lynn, et al.
Publicado: (2019)

A phase 2 trial exploring the clinical and correlative effects of combining doxycycline with bone-targeted therapy in patients with metastatic breast cancer
por: Addison, C.L., et al.
Publicado: (2016)

Defining Zoledronate’s Duration of Action and Optimal Dosing Interval for an Effective Therapy
por: Silverman, Stuart L.
Publicado: (2010)

Dosing of zoledronic acid with its anti-tumor effects in breast cancer
por: Zhao, Xinmin, et al.
Publicado: (2015)

Single Dose Therapy of Zoledronic Acid for the Treatment of Transient Osteoporosis of Hip
por: Agarwala, Sanjay, et al.
Publicado: (2019)

Low-dose zoledronate for the treatment of bone metastasis secondary to prostate cancer
por: Akoury, Elie, et al.
Publicado: (2019)

Patient perceptions and expectations regarding imaging for metastatic disease in early stage breast cancer
por: Simos, Demetrios, et al.
Publicado: (2014)

Primary Febrile Neutropenia Prophylaxis for Patients Who Receive FEC-D Chemotherapy for Breast Cancer: A Systematic Review
por: Fernandes, Ricardo, et al.
Publicado: (2017)

Evaluating the Feasibility of Performing Window of Opportunity Trials in Breast Cancer
por: Arnaout, Angel, et al.
Publicado: (2015)

Three-Year Outcomes Following Permissive Cardiotoxicity in Patients on Trastuzumab
por: Zhou, Shijie, et al.
Publicado: (2023)

Generalizability of toxicity data from oncology clinical trials to clinical practice: toxicity of irinotecan-based regimens in patients with metastatic colorectal cancer
por: Tam, V.C., et al.
Publicado: (2009)

Effect of acetaminophen and fluvastatin on post-dose symptoms following infusion of zoledronic acid
por: Silverman, S. L., et al.
Publicado: (2010)

Dose-dependent inhibitory effects of zoledronic acid on osteoblast viability and function in vitro
por: HUANG, XIN, et al.
Publicado: (2016)

Collapsing Focal Segmental Glomerulosclerosis Resulting from a Single Dose of Zoledronate
por: Neyra, Javier A., et al.
Publicado: (2014)

High doses of zoledronic acid induce differential effects on femur and jawbone microstructure
por: Soares, Mariana Q. S., et al.
Publicado: (2022)

Integrating Systematic Reviews into Supportive Care Trial Design: The Rethinking Clinical Trials (REaCT) Program
por: Alshamsan, Bader, et al.
Publicado: (2022)

Pertuzumab Cardiotoxicity in Patients With HER2-Positive Cancer: A Systematic Review and Meta-analysis
por: Alhussein, Muhammad Mustafa, et al.
Publicado: (2021)

Cost-effectiveness of single-dose zoledronic acid for nursing home residents with osteoporosis in the USA
por: Ito, Kouta
Publicado: (2018)

Anti-Tumor Effects of Low Dose Zoledronate on Lung Cancer-Induced Spine Metastasis
por: Akoury, Elie, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_msidbliqsvqqpud3k4onbq9al2